CHU DE Poitiers
Poitiers, 86021, France
NCT Number: NCT03211676
The aim of this study is to evaluate the removal of midle molecules and inflammatory cytokines with the Theranova-500 ™ dialyzer (medium cut-off membrane, Baxter®) versus a high flux dialyzer Elisio-21H ™ (High-flux membrane, Nipro®) in chronic hemodialysis.
Evaluation of nutritional parameters, inflamatory parameters and oxidative stress will also be carried out.
Finally, the investigators will compare hepcidin levels and the erythropoietin resistance index between the two groups.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Poitiers, 86021, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
hemodialysis with Theranova-500 dialyzer.
hemodialysis with Elisio-21H dialyzer
Time frame: After 3 months
myoglobin Reduction ratio.
Time frame: After 3 months
Reduction rate and clearances of beta2 microglobulin
Time frame: After 3 months
Reduction ratio and clearances of urea
Time frame: After 3 months
Reduction ratio and clearances of creatinine
Time frame: After 3 months
Reduction ratio and clearances of interleukin 6
Time frame: After 3 months
Reduction ratio and clearances of IL-1beta
Time frame: After 3 months
Reduction ratio and clearances of TNF alpha
Time frame: After 3 months
Reduction ratio and clearances of leptin
Time frame: After 3 months
Reduction ratio and clearances of alpha 1 microglobulin
Time frame: After 3 months
Reduction ratio and clearances of retinol binding protein
Time frame: After 3 months
Reduction ratio and clearances of hyaluronic acid
Time frame: After 3 months
Reduction ratio and clearances of FGF 23
Time frame: After 3 months
Reduction ratio and clearances of prolactin
Time frame: After 3 months
Reduction ratio and clearances of free light chain kappa
Time frame: After 3 months
Reduction ratio and clearances of free light chain lambda
Time frame: After 3 months
comparison of average of pre dialysis level of hepcidin
Time frame: After 3 months
comparison of average of pre dialysis level of superoxide dismutase
Time frame: After 3 months
comparison of average of pre dialysis level of isoprostan
Time frame: After 3 months
comparison of average of pre dialysis level of human oxidized LDL
Time frame: After 3 months
comparison of average of pre dialysis level of albumin
Time frame: After 3 months
comparison of average of pre dialysis level of prealbumin
Time frame: After 3 months
comparison of average of post dialysis level of albumin
Time frame: After 3 months
comparison of average level of midlle molecules and albumin in dialysate
Time frame: After 3 months
Comparison of the erythropoietin resistance index
Time frame: After 3 months
comparison of average of predialysis hemoglobin levels
Time frame: After 3 months
comparison of average of pre dialysis level of CRP
Time frame: After 3 months
comparison of average of pre dialysis level of SAA
Poitiers University Hospital
Other
Comparison of Hemodialysis With Medium Cut-off Dialyzer (Theranova) and High Flux Dialyzer on Removal of Small and Middle Size Molecules, Inflammatory Parameters and Oxidative Stress. An Open Cross Over Randomized Study
Acronym: THERANOVA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03674307
Cardiovascular Diseases, Chronic Disease
Tucson, Arizona, United States
View Trial DetailsNCT06515899
Chronic Disease, Disease Attributes
Stevenage, Hertfordshire, United Kingdom
View Trial DetailsNCT03719339
Acute Cellular Graft Rejection, Antibody-mediated Rejection
La Jolla, California, United States
View Trial DetailsNCT04817774
Chronic Disease, Disease Attributes
Leuven, Belgium
View Trial Details